You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
18 September 2023
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
9 November 2022
Atriva Therapeutics appoints Christian Pangratz as CEO, implementing planned management change
18 October 2022
Atriva Therapeutics announces appointment of CSO and senior leaders to Clinical Development Team
20 September 2022
Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19
28 March 2022
Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron
10 January 2022
Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections